Want the key stats in the sections on this page as a document? or looking for a stats report of the in-depth stats? Use the print function at the bottom of any Cancer Stats page Share this page > Print or your browser options to print or save.
Eye cancer statistics
New cases of eye cancer, 2014, UK
Deaths from eye cancer, 2014, UK
Survive eye cancer for 10 or more years, 2009-2013, England
Preventable cases of eye cancer, UK
- There were 750 new cases of eye cancer in the UK in 2014, that’s around 2 cases diagnosed every day.
- Eye cancer accounts for less than 1% of all new cases in the UK (2014).
- In males, there were around 400 cases of eye cancer diagnosed in the UK in 2014.
- In females, there were around 350 cases of eye cancer diagnosed in the UK in 2014.
- Almost half (47%) of eye cancer cases in the UK each year are diagnosed in people aged 65 and over (2012-2014).
- Incidence rates for eye cancer in the UK are highest in people aged 85+ (2012-2014).
- Since the early 1990s, eye cancer incidence rates have remained stable in the UK. The trend is similar in males and females.
- Over the last decade, eye cancer incidence rates have increased by around a fifth (19%) in the UK, with similar trends in males and females.
- Most eye cancers occur in the choroid.
- 1 in 1,205 men and 1 in 1,330 women will be diagnosed with eye cancer during their lifetime.
- An estimated 5,800 people who had previously been diagnosed with eye cancer were alive in the UK at the end of 2010.
- There were around 120 eye cancer deaths in the UK in 2014, that’s more than 2 deaths every week.
- Eye cancer accounts for less than 1% of all cancer deaths in the UK (2014).
- In males in the UK, there were around 55 eye cancer deaths in 2014.
- In females in the UK, there were around 65 eye cancer deaths in 2014.
- Almost 6 in 10 (56%) eye cancer deaths in the UK each year are in people aged 70 and over (2012-2014).
- Mortality rates for eye cancer in the UK are highest in people aged 90+ (2012-2014).
- Since the early 1970s, eye cancer mortality rates have decreased by more than a half (54%) in the UK, with a similar decrease in males (56%) and females (54%).
- Over the last decade, eye cancer mortality rates have remained stable in the UK, for males and females combined and separately.
- 6 in 10 (60%) people diagnosed with eye cancer in England survive their disease for ten years or more (2009-2013).
- 7 in 10 (70%) people diagnosed with eye cancer in England survive their disease for five years or more (2009-2013).
- 95% of people diagnosed with eye cancer in England survive their disease for one year or more (2009-2013).
- Eye cancer 10-year survival in England is similar in men and women (2009-2013).
- Eye cancer survival in England is highest for adults diagnosed aged under 50 years old (2009-2013).
- Around 8 in 10 people in England diagnosed with eye cancer aged 15-49 survive their disease for five years or more, compared with almost two-thirds of people diagnosed aged 70-89 (2009-2013).
- A person’s risk of developing cancer depends on many factors, including age, genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors).
- 2% (3% in males and less than 1% in females) of eye cancer cases each year in the UK are linked to major lifestyle and other risk factors.
- Certain occupational exposures may relate to higher eye cancer risk but evidence is unclear; these would account for an estimated 2% of eye cancer cases in the UK.
- ‘Two-week wait’, ‘31-day wait’ and ’62-day wait’ standards are met by all countries for brain and CNS tumours.
- Around 9 in 10 patients had a ‘very good’ or ‘excellent’ patient experience.
- Around 9 in 10 patients are given the name of their Clinical Nurse Specialist.
The latest statistics available for eye cancer in the UK are; incidence 2014, mortality 2014 and survival 2009-2013. Risk factors information are in production.
The ICD code for eye cancer is ICD-10 C69.
European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.
Lifetime risk estimates were calculated using incidence, mortality, population and all-cause mortality data for 2010-2012 due to the small number of cases.
Most cases of eye cancer are in the uvea; accordingly most evidence cited on our risk factors page is for uveal melanoma specifically rather than eye cancer overall. The specific cancer type is stated where possible.
Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. Eye cancer is part of the group 'Brain and CNS tumours' for cancer waiting times data. Codes vary per country but broadly include: peripheral nerves and autonomic nervous system, eye and adnexa, meninges, brain, spinal cord, cranial nerves and other parts of the CNS, and secondary cancers of brain and cerebral meninges and other and unspecified parts of nervous system.
Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.
You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:
Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.
When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or
We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.